Biden announces stunning new tax rates for the wealthiest Americans


Axios

The next generation coronavirus vaccine will not come so soon

The flood of cash from Operation Warp Speed ​​has helped guide many biotech companies into the competition for coronavirus vaccines, but the incentive to continue working on new competitors is not very strong. Significant reason: The first cash flood went well — providing multiple highly effective vaccines in record time. However, in other disease areas, 2nd and 3rd generation vaccines are usually the main products. And the first COVID-19 vaccine is not always optimal for the whole world. Get the right market news for your time at Axios Markets. Subscribe for free. The big picture: Pfizer and Modana RNA vaccines are very effective. Also, in the United States and other wealthy countries, refrigeration requirements and multiple doses can be easily managed. “The motivation for developing a vaccine to replace such a vaccine is not overwhelming,” said NIAID director Anthony Fauci. The US government has little reason to spend billions of dollars on subsequent research, and the vaccine market relies heavily on government and non-governmental agencies. Yes, but: Each existing vaccine has some characteristics and is not a perfect candidate for use in low-income countries, and ultimately, vaccination as much as possible in the world is not possible. It will be the self-interest of a rich country. Both Pfizer and Moderna are two shots and need to be stored at very low temperatures. AstraZeneca is a two-shot and has been plagued by bad headlines and safety concerns from European regulators. Johnson & Johnson is a one-shot, but it has also suffered a reputational decline due to very rare side effects. Conspiracy: There is no traditional market incentive to develop cheaper competing products, especially since much of the remaining needs are in poor countries, “said Professor Craig Garthwaite of Northwestern University,” low prices for another vaccine. If you’re trying to develop in, that’s probably not a good incentive. ” Efficacy, safety, cost, ease of use, speed of development for a new generation covering variants, and manufacturing scalability, “said Krishna Udayakumar, Founding Director of the Duke Global Health Innovation Center. “For long-term sustainability, new vaccines probably need to be better in one or more of these domains.” What we are paying attention to: The vaccine pipeline is completely dry. Not — Novavax is likely to seek approval soon and other vaccines are still under development “Access to capital may be even more difficult in the future, but still with significant R & D support There seem to be several vaccine candidates, “said Udaya Kumar. These include vaccines that use a variety of platforms and vaccines that can be administered orally. Existing vaccine manufacturers will continue to work on their products. Pfizer is investigating whether vaccines can be stored at warmer temperatures. This makes it more accessible around the world. I think there is a strong interest in access to mRNA vaccines in low and middle income countries. I also think that companies are doing a lot of research to get rid of the cold. “They have chain requirements,” Forch said. “There will always be individual researchers working on new platform technologies.” “They won’t be done at Operation Warp Speed ​​levels. These will be done by the individual grantees who devised the concept.” Axios Details: To get the latest market trends at Axios Markets Please sign up. Subscribe for free.